DAB2IP and hepatocellular carcinoma: Recently, there has been increasing evidence that reduced expression of DAB2IP occurs in several types of human malignancies, including prostate cancer [6], lung cancer [7], hepatocellular carcinoma [8], renal cancer [9], and breast cancer [10].